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Acute generalized exanthematous pustulosis is a rare severe pustular cutaneous adverse reaction characterized by 
a rapid clinical course with typical histological findings. It is accompanied by fever and acute eruption of non-follicular 
pustules overlying erythrodermic skin. The causative agents are most frequently antibacterial drugs. We present a patient 
with acute generalized exanthematous pustulosis caused by methylene blue and indigotin dyes.
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INTRODUCTION
Acute generalized exanthematous pustulosis (AGEP) 
is a rare and severe cutaneous hypersensitivity reaction 
pattern that resembles pustular psoriasis. In over 90% 
of cases, the causative agents are systemic drugs, par-
ticularly anti-infectious agents such as aminopenicillins 
and macrolides [1]. Antifungal agents, non-steroidal anti-
inflammatory drugs, analgesics, antiarrhythmics, anticon-
vulsants, and antidepressants may also be responsible. In 
addition to drugs, other triggers have also been identified 
including exposure to mercury and viral infections [1,2]. 
Proposed diagnostic criteria include 1) acute develop-
ment of numerous, small (< 5 mm), mainly nonfollicular 
pustules arising on widespread edematous erythema; 2) 
fever > 38ºC; 3) neutrophilia with or without mild eosino-
philia; 4) spontaneous resolution of pustules in < 15 days; 5) 
subcorneal or intraepidermal pustules on a skin biopsy [3].
We describe the first reported case of AGEP associated 
with blue-dye hypersensitivity. 
CASE REPORT
A 69-year-old male was referred to our clinic because of 
generalized pruritus and erythema accompanied by high 
fever. He had a history of hypertension for 20 years and 
had been taking 16 mg candesartan cilexetil tablets. The 
day before admission, he was given tablets three times 
daily for dysuria that included helmitol, methylene blue, 
and  indigotin. On physical examination, his body temper-
ature was 37ºC. He had pruritic erythematous lesions on 
the trunk and upper extremities. He was diagnosed with 
a drug reaction due to the drug used for dysuria. The drug 
was discontinued, and he was given oral antihistamine 
therapy. After 24 hours, he was admitted with complaints 
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of high fever (40ºC), increased number of skin lesions, 
arthralgia, and headache. A dermatological examination 
revealed exanthema over 60% of the body accompanied 
by angioedema of the lips and eyelids. The rash was com-
posed of scattered nonfollicular small pustules over an 
erythematous background (Fig. 1). No ocular or mucous 
membrane symptoms were present. He was clinically di-
agnosed with AGEP and hospitalized. A pustule culture 
was free of organisms. The only abnormal laboratory find-
ing was blood eosinophilia (1.25 × 10
9/L). Other laboratory 
test results, such as a neutrophil count and serological re-
sults were within normal limits. A punch biopsy was taken 
from the erythematous and pustular skin area. A histo-
pathological examination of the skin biopsy revealed sub-
corneal/superficial intraepidermal pustule formation and 
a collection of neutrophils including eosinophils. Some 
neutrophilic exocytosis and mild spongiosis was present 
around the pustules in the epidermis. The upper dermis 
was edematous and contained a moderate inflammatory 
cell infiltrate with some eosinophils in the perivascular ar-
eas (Fig. 2). The histopathological diagnosis was consistent 
with AGEP. He was administered an antihistamine tablet 
(5 mg/day levocetirizine) and both oral (48 mg/day meth-
ylprednisolone) and topical (methylprednisolone acetate) 
corticosteroid therapy. Omeprazol (20 mg, bid) was added 
to his therapy regimen. On the second day of hospitaliza-
tion, he reported bloody feces. 
An esophagogastroduodenoscopy showed disseminated 
erosive gastritis of the stomach mucosa.
The pustular skin lesions and systemic findings 
resolved within 48 hours of hospitalization, and a second 
endoscopic examination was normal. Oral corticosteroid 
therapy was stopped on the fifth day. He continued to 
take his previous antihypertensive therapy (candesartan 
cilexetil) without any adverse reactions. He has not taken 
any other medications or any drug or food containing 
methylene blue or indigotin dye. He was discharged 
without antihistamine or corticosteroid therapy and 
invited to follow-up visits. Skin lesions and systemic 
symptoms had cleared up completely on day 20 after his 
first admission.
At the third examination 2 months after discharge, he 
disclosed that he had accidentally used another drug for 
dysuria containing helmitol. However, he did not report 
any adverse reactions such as those reported previously. 
Therefore, helmitol was omitted from the skin tests. 
Figure 1. Pustules on diffuse erythema. Multiple pustular lesions 
on an erythematous background.
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Figure 2. The histopathological diagnosis was consistent with 
acute generalized exanthematous pustulosis. A skin biopsy showed 
subcorneal/superficial intraepidermal pustule formation and a 
collection of neutrophils, including eosinophils. (A) Superficial 
epidermal pustulation (H&E, × 40). (B)  Neutrophilic spongiosis 
(H&E, × 100).362    The Korean Journal of Internal Medicine Vol. 26, No. 3, september 2011
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Skin prick tests were performed at 2 months after 
discharge using methylene blue and the coloring agent of 
the tablets, indigotin, diluted in water. The prick test was 
negative. Patch tests were performed with the same agent 
diluted to 20% in petrolatum. Patch tests were read 48 and 
72 hours after application and were negative.
DISCUSSION
Methylene blue and indigotin are dyes are currently used 
as a tracer for detecting urinary and digestive fistulas, for 
assessing tubal permeability, or in sentinel lymph node 
biopsies [4-6]. 
Methylene blue is used as a treatment for some clinical 
conditions and for diagnostic purposes; it is an alternative 
choice for treating hypotension during septic shock and 
for treating anaphylaxis, depending on the radiocontrast 
material, to balance arterial blood pressure [7]. It can also 
be used at lower doses to treat methemoglobinemia [8]. 
Indigo, which is produced by fermenting the Indigofera 
tinctoria plant, has been used as a dye in denims, blue 
jeans, and other fabrics. Indigotin and indigocarmine 
are indigo derivatives that are widely used as synthetic 
coloring agents in the food and cosmetic industries in 
many countries. Moreover, indigocarmine is considered 
biologically inert and extremely safe. 
Many case reports of allergic adverse reactions to blue 
dyes have been described. The symptoms vary from 
urticaria to anaphylaxis [9-11].
The physiopathological mechanisms of AGEP remain 
uncertain, but drug-specific positive patch test responses 
and in vitro lymphocyte proliferative responses in patients 
with a history of AGEP strongly suggest that this adverse 
cutaneous reaction occurs via a drug-specific T-cell-
mediated process [12].
Viral infections are the cause of most drug eruptions in 
children, whereas drugs are more frequently responsible 
in adults [3]. In this case, the history and clinical course 
were consistent with a drug reaction; therefore, we did not 
conduct serological test to determine  a viral etiology.
It may be clinically difficult to distinguish AGEP from 
other pustular dermatoses, and a histopathological 
examination is helpful. A histological analysis reveals 
subcorneal and/or intraepidermal spongiform pustulation 
and subcorneal collections of neutrophils with papillary 
dermal edema and a perivascular infiltrate consisting of 
neutrophils and sometimes eosinophils.
Pustules are commonly localized in the main folds 
(neck, axillae, and groin), trunk, and upper extremities. 
Additional skin symptoms, such as edema of the face and 
hands, purpura, vesicles, blisters, and “atypical” targets, 
may also be present. Mucous membrane involvement is 
rare, usually mild, and generally restricted to the oral 
mucosa. The clinical course of the skin reaction is very 
typical. The time interval between drug administration 
and skin eruption is normally less than 2 days. Skin 
symptoms usually resolve within a few days without 
treatment.
No specific treatment is recommended for AGEP except 
supportive care according to the clinical situation. It is a 
self-limited disease with a favorable prognosis.
However, AGEP may be potentially life threatening, 
particularly in older patients. The mortality rate of AGEP 
is approximately 2% [13]. Therefore, identifying and 
promptly removing the culprit drug is important.
Patch testing may sometimes contribute to an AGEP 
diagnosis; however, it did not help in this case. The 
sensitivity of patch testing to drugs responsible for AGEP 
is approximately 50% [14]. 
We report an interesting case of pustular eruption that 
presented with nonfollicular sterile pustules with diffuse 
edema and erythema on the face, trunk, intertriginous 
areas, and extremities in association with a high fever.
Although there are cases of dermatological symptoms 
due to blue dyes, this is the first case report of AGEP due to 
blue dyes [9-11]. Our AGEP diagnosis, which was aided by 
a skin biopsy and clinical findings, was confirmed.
Although skin epidermal prick test and patch test results 
did not support our diagnosis, similar negative test results 
have been reported in some previous cases of drug-related 
AGEP. This can be explained by the activation of different 
immunological mechanisms based on the difference in the 
entrance and contact of the drugs. Positive skin test results 
are not a typical finding of AGEP. 
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